Routine BRCA testing for ovarian cancer: a game changer in the making?

NCT ID NCT06274541

First seen Apr 18, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study looked at whether it's practical to routinely test tumor tissue from ovarian cancer patients for BRCA gene mutations. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. The goal was to see if this testing could be done smoothly in the clinic and how it might affect treatment choices and costs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bon Secours

    Cork, Munster, Ireland

  • Cork University Hospital

    Cork, Munster, Ireland

  • Mater Misericordiae University Hospital / Mater Private Hospital

    Dublin, Leinster, Ireland

  • St James's Hospital

    Dublin, Leinster, Ireland

  • University Hospital Limerick

    Limerick, Munster, Ireland

Conditions

Explore the condition pages connected to this study.